Trevi Therapeutics Inc.

Company Overview

Business Model: Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio (oral nalbuphine ER). Haduvio is an investigational therapy targeting chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). The company's core value proposition is to address high unmet medical needs in these chronic cough conditions, for which there are currently no FDA-approved therapies for IPF or non-IPF ILD, and no U.S. approved therapies for RCC. Haduvio acts as a kappa receptor agonist and a mu receptor antagonist (KAMA), modulating opioid receptors involved in the cough reflex. The company has not generated any revenue from product sales since its inception.

Market Position: Trevi Therapeutics, Inc. operates in a highly competitive biopharmaceutical industry. For IPF-related and non-IPF ILD-related chronic cough, there are no FDA-approved therapies, positioning Haduvio as a potential first-in-class treatment if approved. In RCC, Haduvio would compete with product candidates in clinical development, such as camlipixant by GSK plc and taplucainium by Nocion Therapeutics Inc. Gefapixant, developed by Merck & Co., Inc., is approved for RCC in Japan, the United Kingdom, Switzerland, and the E.U., but its FDA application was withdrawn. Haduvio also faces competition from therapeutics not specifically approved for chronic cough, including benzonatate, opioids, corticosteroids, proton-pump inhibitors, and neuromodulators. The company aims to differentiate Haduvio through its dual mechanism of action and potential safety profile.

Recent Strategic Developments:

• IPF-related Chronic Cough Program: In June 2025, Trevi Therapeutics, Inc. announced positive topline results from its Phase 2b CORAL trial, demonstrating statistically significant reductions in 24-hour cough frequency across all dose groups (108 mg BID, 54 mg BID, and 27 mg BID) at Week 6 compared to placebo. The company completed an End-of-Phase 2 meeting with the FDA, gaining alignment on plans for two pivotal Phase 3 clinical trials and remaining Phase 1 studies. The first Phase 3 trial is planned for initiation in Q2 2026 (approx. 300 patients, 52 weeks fixed dosing with 54 mg BID, primary endpoint at 24 weeks), and the second in H2 2026 (approx. 130 patients, 12 weeks fixed dosing with 54 mg BID).
• Non-IPF ILD-related Chronic Cough Program: Trevi Therapeutics, Inc. plans to initiate an adaptive design Phase 2b clinical trial for non-IPF ILD-related chronic cough in H2 2026, subject to FDA protocol review.
• RCC Program: In March 2025, positive topline data from the Phase 2a RIVER trial in RCC patients showed a statistically significant 67% reduction in 24-hour cough frequency from Baseline (57% placebo-adjusted) at Day 21. A Phase 2b trial for RCC is expected to initiate in Q2 2026 in the United Kingdom, Canada, and potentially other European countries, to determine Phase 3 doses and further characterize safety.
• NDA Supportive Studies: Ongoing Phase 1 studies include a respiratory safety study (TIDAL, expected completion mid-2026) and drug-drug interaction, food effect, and hepatic/renal impairment studies.
• Human Abuse Potential (HAP) Study: In December 2024, positive topline results showed statistically significant lower "Drug Liking" for clinical doses of oral nalbuphine (81mg and 162mg) compared to 6mg IV butorphanol.
• Drug-Drug Interaction Study: Completed in October 2025, concluding no clinically meaningful pharmacokinetic findings for Haduvio when co-administered with pirfenidone or nintedanib, thus no dose adjustments are required.

Geographic Footprint: Trevi Therapeutics, Inc. has retained worldwide commercial rights for Haduvio. Clinical trials have been conducted in the U.S., Europe (including the United Kingdom), and Canada. The company plans to market and commercialize Haduvio in the U.S. with its own focused, specialty sales force, targeting pulmonologists and ILD centers of excellence for IPF and non-IPF ILD, and pulmonologists and allergists for RCC. Commercialization outside the U.S. is expected to involve collaboration, distribution, and other marketing arrangements with third parties.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: Not applicable (no revenue)
• Operating Margin: Not applicable (no revenue)
• Net Margin: Not applicable (no revenue)

Investment in Growth:

• R&D Expenditure: $33.5 million (67.9% of total operating expenses)
• Capital Expenditures: $0.012 million (2025) vs. $0.035 million (2024)
• Strategic Investments: Not explicitly detailed as separate line items beyond R&D. The company's primary investment is in the clinical development of Haduvio across its target indications.

Business Segment Analysis

Idiopathic Pulmonary Fibrosis (IPF)-related Chronic Cough Program

Financial Performance:

• Clinical Trial Expense: $7.992 million (-45.3% YoY from $14.615 million in 2024)
• Operating Margin: Not applicable (development stage)
• Key Growth Drivers: Positive topline results from the Phase 2b CORAL trial, demonstrating statistically significant reductions in 24-hour cough frequency across all dose groups (60.2% for 108 mg BID, 53.4% for 54 mg BID, 47.9% for 27 mg BID vs. 16.9% for placebo at Week 6). Rapid reduction in cough frequency observed as early as Week 2. Statistically significant improvements in patient-reported outcomes (CS-NRS, E-RS®: IPF Cough Subscale, LCQ Total Score) for higher doses. Overall alignment with the FDA on the plan for two pivotal Phase 3 clinical trials and remaining Phase 1 studies.

Product Portfolio:

• Haduvio (oral nalbuphine ER) for the treatment of IPF-related chronic cough.
• New product launches or major updates: Not applicable, as Haduvio is an investigational therapy.

Market Dynamics:

• Competitive positioning within segment: No FDA-approved therapies currently exist for IPF-related chronic cough, positioning Haduvio as a potential first-in-class treatment. Development of BI 1839100 by Boehringer Ingelheim for IPF-related chronic cough was terminated in September 2025.
• Key customer types and market trends: Approximately 150,000 U.S. patients with IPF, two-thirds of whom suffer from uncontrolled chronic cough. High unmet need due to significant impact on morbidity, mortality, and quality of life.

Non-IPF Interstitial Lung Disease (non-IPF ILD)-related Chronic Cough Program

Financial Performance:

• Clinical Trial Expense: Included in "Other clinical trials and studies" ($6.219 million in 2025, +44.2% YoY from $4.313 million in 2024).
• Operating Margin: Not applicable (development stage)
• Key Growth Drivers: High unmet need, with approximately 228,000 adults in the U.S. and over 1 million worldwide suffering from non-IPF ILDs, and 50-60% experiencing uncontrolled chronic cough. Cough may be an independent predictor of disease progression.

Product Portfolio:

• Haduvio (oral nalbuphine ER) planned for development for non-IPF ILD-related chronic cough.
• New product launches or major updates: Not applicable, as Haduvio is an investigational therapy.

Market Dynamics:

• Competitive positioning within segment: No approved therapies for non-IPF ILD-related chronic cough.
• Key customer types and market trends: Patients with various non-IPF ILDs experiencing chronic cough.

Refractory Chronic Cough (RCC) Program

Financial Performance:

• Clinical Trial Expense: $1.457 million (-75.9% YoY from $6.042 million in 2024).
• Operating Margin: Not applicable (development stage)
• Key Growth Drivers: Positive topline data from the Phase 2a RIVER trial, showing a statistically significant 67% reduction in 24-hour cough frequency from Baseline (57% placebo-adjusted) at Day 21. Statistically significant reductions observed in severe (20+ coughs/hour) and moderate (10-19 coughs/hour) cough subgroups. Rapid reduction in cough frequency seen as early as Day 7.

Product Portfolio:

• Haduvio (oral nalbuphine ER) for the treatment of RCC.
• New product launches or major updates: Not applicable, as Haduvio is an investigational therapy.

Market Dynamics:

• Competitive positioning within segment: RCC affects 2-3 million adults in the U.S. Competitors include camlipixant (GSK plc) and taplucainium (Nocion Therapeutics Inc.). Gefapixant (Merck & Co., Inc.) is approved in some ex-U.S. markets.
• Key customer types and market trends: Adults with persistent cough lasting over eight weeks despite treatment for underlying conditions, including unexplained chronic cough.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: None disclosed.
• Dividend Payments: No cash dividends declared or paid, nor are they anticipated in the foreseeable future.
• Dividend Yield: Not applicable.
• Future Capital Return Commitments: None disclosed.

Balance Sheet Position:

• Cash and Equivalents: $18.9 million (2025) vs. $34.1 million (2024)
• Total Debt: No term loans or significant debt disclosed. Finance lease liabilities were $0.031 million in 2024 and $0 in 2025.
• Net Cash Position: $18.9 million (2025) vs. $34.1 million (2024) (considering only cash and equivalents). Cash, cash equivalents and marketable securities totaled $188.3 million as of December 31, 2025.
• Credit Rating: Not disclosed.
• Debt Maturity Profile: Not applicable, as no significant debt is disclosed.

Cash Flow Generation:

• Operating Cash Flow: $(42.1) million (2025) vs. $(38.3) million (2024)
• Free Cash Flow: Not explicitly calculated, but negative due to operating losses and capital expenditures.
• Cash Conversion Metrics: Not explicitly detailed.

Operational Excellence

Production & Service Model: Trevi Therapeutics, Inc. contracts with third parties for the supply of nalbuphine hydrochloride drug substance and the manufacture of Haduvio tablets for clinical trials, and intends to continue this model for future clinical and commercial supply. The company does not own or operate its own manufacturing facilities. Haduvio is manufactured from readily available starting materials using established, scalable processes.

Supply Chain Architecture: Key Suppliers & Partners:

• Drug Substance Supplier: Par Health (single supplier for nalbuphine hydrochloride drug substance). No agreements guarantee supply quantities or pricing.
• Contract Manufacturers: Third parties for Haduvio tablet manufacturing, storage, packaging, and distribution for clinical trials.
• Contract Research Organizations (CROs): Third parties conduct clinical trials.

Facility Network:

• Manufacturing: Relies on third-party contract manufacturers.
• Research & Development: R&D activities are outsourced to third parties.
• Distribution: Relies on third-party contractors for storage, packaging, and distribution.
• Headquarters: New Haven, Connecticut (12,500 sq ft leased office space, lease expires February 2028).

Operational Metrics: Not explicitly disclosed beyond clinical trial progress and safety profiles.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: Plans to establish its own focused, specialty sales force in the U.S. for Haduvio, if approved.
• Channel Partners: Expects to utilize collaboration, distribution, and other marketing arrangements with one or more third parties to commercialize Haduvio outside the U.S.
• Digital Platforms: Not explicitly detailed.

Customer Portfolio: Enterprise Customers: Not applicable as the company is pre-commercial. Customer Concentration: Not applicable.

Geographic Revenue Distribution: Not applicable, as the company has not generated any revenue from product sales.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The biopharmaceutical industry is intensely competitive, subject to rapid and significant change. The market for chronic cough, particularly in IPF and non-IPF ILD, represents a high unmet medical need with no currently approved therapies. The RCC market has some approved therapies outside the U.S. and several in development. Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• GSK plc: Developing camlipixant (P2X3 antagonist) for RCC.
• Merck & Co., Inc.: Developed gefapixant (P2X3 antagonist), approved for RCC in Japan, the United Kingdom, Switzerland, and the E.U. (FDA application withdrawn).
• Nocion Therapeutics Inc.: Developing taplucainium (charged sodium channel blocker) for RCC.
• Boehringer Ingelheim: Development of BI 1839100 (TRPA1 antagonist) for IPF-related chronic cough and progressive pulmonary fibrosis was terminated in September 2025.

Emerging Competitive Threats: New entrants and disruptive technologies are a constant threat in the biopharmaceutical industry. The company also competes with off-label use of existing therapeutics such as benzonatate, opioids, corticosteroids, proton-pump inhibitors, and neuromodulators.

Competitive Response Strategy: Trevi Therapeutics, Inc. aims to leverage Haduvio's unique mechanism of action and clinical trial results to establish market position. The company plans to build a focused, specialty sales force in the U.S. and seek collaborations for ex-U.S. commercialization.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics:

• Unproven Approach: Haduvio's approach to chronic cough is unproven, as nalbuphine has not been approved for cough indications.
• High Placebo Response Rates: Use of patient-reported outcome assessments (PROs) in clinical trials and historically high placebo response rates may delay or impair development.
• Competition: Intense competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies, including those developing more effective, safer, or less costly alternatives.
• Market Acceptance: Even if approved, Haduvio may fail to achieve market acceptance by physicians, patients, and third-party payors, especially given potential reluctance to prescribe opioid-based therapies.
• Resource Allocation: Risk of expending limited resources on less profitable or less successful product candidates/indications.

Operational & Execution Risks

Supply Chain Vulnerabilities:

• Single Supplier Dependency: Reliance on Par Health as a single supplier for nalbuphine hydrochloride drug substance without guaranteed supply or pricing.
• Third-Party Manufacturing: Dependence on contract manufacturers for drug substance and product, entailing risks of delays, termination, non-compliance, and misappropriation of proprietary information.
• Capacity Constraints: Potential for delays in identifying or qualifying replacement manufacturers if existing ones become unavailable.
• Clinical Trial Delays: Delays or difficulties in patient enrollment, unforeseen events, or regulatory requirements could prolong clinical development and increase costs.
• Adverse Events: Identification of adverse events or undesirable side effects during development could delay or prevent marketing approval or limit use.
• Opioid Class Label: Haduvio is likely to carry an opioid class label warning for respiratory depression, potentially restricting its use.
• Controlled Substance Classification: Risk that the U.S. Drug Enforcement Agency could classify Haduvio as a controlled substance, leading to restrictive marketing and distribution regulations.

Financial & Regulatory Risks

Market & Financial Risks:

• Significant Losses: Incurred significant losses since inception and expects to continue incurring increasing losses, with no guarantee of achieving or maintaining profitability.
• Additional Funding: Requires substantial additional funding beyond existing cash, cash equivalents, and marketable securities to complete development and commercialization. Failure to raise capital could force delays or abandonment of programs.
• Dilution: Raising additional capital through equity offerings may dilute stockholder ownership.
• Product Liability: Inherent risk of product liability claims from clinical trials and commercialization, potentially leading to substantial liabilities.
• Reimbursement: Commercial success depends on third-party payor coverage and adequate reimbursement, which is uncertain and subject to cost-containment measures and healthcare reforms.
• Pricing Regulations: Potential for unfavorable pricing regulations and healthcare reform initiatives to limit product prices and revenue.

Regulatory & Compliance Risks:

• Regulatory Approval Uncertainty: Lengthy, expensive, and uncertain regulatory approval process in the U.S. and foreign jurisdictions.
• 505(b)(2) Pathway: Reliance on the Section 505(b)(2) regulatory pathway for Haduvio carries risks if the FDA does not agree or if the requirements change.
• Foreign Clinical Data Acceptance: FDA may not accept data from trials conducted outside the U.S., requiring additional costly and time-consuming trials.
• Post-Marketing Restrictions: Approved products are subject to ongoing regulatory requirements, post-marketing restrictions, or potential withdrawal from the market.
• Off-Label Promotion: Risk of penalties for promoting Haduvio for unapproved uses.
• Government Agency Disruptions: Funding cuts, personnel losses, regulatory reform, or government shutdowns could delay FDA guidance, review, and approval.
• Data Privacy & Security: Compliance with global privacy laws (GDPR, CCPA, CPRA, etc.) is costly and complex, with risks of fines, litigation, and reputational harm from non-compliance or data breaches.
• Artificial Intelligence Risks: Security risks to confidential information, proprietary information, and personal data from AI use by vendors or bad actors.

Geopolitical & External Risks

Geopolitical Exposure:

• International Trade Policies: Changes in U.S. and international trade policies, including tariffs, could impact costs, supply chains, and market access.
• Foreign Regulatory Changes: Evolving regulatory landscapes in foreign jurisdictions (e.g., E.U. pharmaceutical legislation review) could impact approval timelines and exclusivity.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas:

• Opioid Receptor Modulation: Focus on Haduvio's mechanism as a kappa receptor agonist and mu receptor antagonist (KAMA) to target opioid receptors involved in chronic cough.
• Extended-Release Formulation: Development of an oral extended-release formulation of nalbuphine.
• Innovation Pipeline: Haduvio is the sole product candidate, with development focused on chronic cough in IPF, non-IPF ILD, and RCC.

Intellectual Property Portfolio:

• Patent Strategy: Owns six U.S. patents, 22 foreign patents, and multiple pending U.S. and foreign patent applications related to methods of use of Haduvio (expiring between 2032 and 2045). A U.S. patent covering use for IPF-related chronic cough was issued, and a notice of allowance for a U.S. patent application covering use in IPF patients with hepatic impairment was received in February 2025 (expiring 2042).
• Licensing Programs: Exclusive worldwide sublicensable license from Keenova Therapeutics plc for patent rights and know-how related to nalbuphine hydrochloride formulations, including Haduvio. Licensed intellectual property includes six U.S. patents and four foreign patents related to Haduvio formulation (expiring between 2026 and 2029). Also in-licensed three U.S., one European, one Japanese, and one Canadian patent related to nalbuphine use in movement disorders (expiring 2032).
• IP Litigation: No material IP litigation disclosed.
• Composition of Matter: Does not own or exclusively license any composition of matter patents for Haduvio.

Technology Partnerships:

• Strategic Alliances: Exclusive license agreement with Keenova Therapeutics plc for Haduvio.
• Research Collaborations: Not explicitly detailed beyond general reliance on consultants and advisors.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: Not explicitly detailed beyond general statements about attracting and retaining qualified personnel.

Board Composition: Information incorporated by reference from the 2026 Annual Meeting of Stockholders Proxy Statement.

Human Capital Strategy

Workforce Composition:

• Total Employees: 34 employees as of December 31, 2025.
• Geographic Distribution: Not explicitly detailed, but operations are in New Haven, Connecticut, and clinical trials are conducted internationally.
• Skill Mix: 21 employees in research and development, 13 in general management and administration (including finance and commercial).

Talent Management: Acquisition & Retention:

• Hiring Strategy: Aims to attract and retain highly qualified scientific, clinical, manufacturing, and sales/marketing personnel.
• Retention Metrics: Not explicitly disclosed, but the industry experiences a high rate of turnover.
• Employee Value Proposition: Benchmarks total rewards (compensation, 401(k), health/welfare benefits, paid time off, personal leave) against industry peers.

Diversity & Development:

• Diversity Metrics: Not explicitly disclosed.
• Development Programs: Not explicitly detailed.
• Culture & Engagement: Believes it maintains good relations with employees.

Regulatory Environment & Compliance

Regulatory Framework: Industry-Specific Regulations:

• U.S. Drug Regulation: Subject to extensive regulation by the FDA under the Federal Food, Drug, and Cosmetic Act (FDCA), including preclinical testing (GLP), clinical trials (cGCP), IND/NDA processes, post-approval requirements (REMS, post-marketing studies), and promotion/advertising rules.
• E.U. Medicinal Product Regulation: Subject to E.U. Clinical Trials Regulation (CTR), Marketing Authorization Application (MAA) procedures (centralized, decentralized, mutual recognition), and post-authorization requirements (pharmacovigilance, cGMP, promotion rules).
• U.K. Medicinal Product Regulation: Subject to Medicines and Healthcare Products Regulatory Agency (MHRA) approval, Human Medicines Regulations 2012 (HMR), and the new International Recognition Procedure (IRP) as of January 1, 2024.
• Healthcare Fraud & Abuse: Subject to federal Anti-Kickback Statute, False Claims Act, HIPAA, Physician Payments Sunshine Act, and analogous state and foreign laws.
• Data Privacy & Security: Subject to GDPR in the E.U., U.K. Data Protection Act, and various U.S. state laws (e.g., CCPA, CPRA, Washington's My Health My Data Act).

Trade & Export Controls:

• Export Restrictions: Subject to various laws, regulations, and executive orders restricting the use and dissemination of classified information, products, and technical data outside the U.S.
• Sanctions Compliance: Not explicitly detailed, but generally subject to sanctions compliance.

Legal Proceedings: Trevi Therapeutics, Inc. is not subject to any material legal proceedings.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: Not explicitly stated, but the company has incurred significant net operating losses.
• Geographic Tax Planning: Not explicitly detailed.
• Tax Reform Impact: The Inflation Reduction Act of 2022 (IRA) and the One Big Beautiful Bill Act (OBBBA) in 2025 have implications for Medicare Part D, price negotiations, inflation rebates, and tax provisions (e.g., excise tax on stock repurchases, R&D expensing). The company is evaluating the impact of the OBBBA.

Insurance & Risk Transfer

Risk Management Framework:

• Insurance Coverage: Maintains product and clinical trial liability insurance of at least $10.0 million in aggregate. Does not maintain insurance for environmental liability or toxic tort claims.
• Risk Transfer Mechanisms: Not explicitly detailed beyond insurance.